1. Israel Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Eocene Ltd.

Eocene Ltd.

EOCN
Eocene Ltd.US flagNASDAQ
3.61
USD
+0.21
- -
3.76MMarket Cap
Eocene Ltd.
EOCN
(NASDAQ)

Recent

price

3.61

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
59.12
125.13
161.81
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-894.6
-2,358.69
-1,269.77
-1,378.05
-2,146.22
-1,418.41
-782.53
-1,395.51
-1,946.88
-1,900.77
-1,023.25
-239.59
-64.61
-19.13
-13.84
Basic EPS, GAAP
-883.81
-342.24
-1,396.43
-1,120.01
-1,537.66
-1,393.03
-723.54
-1,019.57
-1,781.77
-1,926.29
-1,059.85
-212.73
-50.54
-11.72
-10.42
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-266.96
-263.19
4,070.45
2,795.15
1,312.83
1,575.72
6,021.79
4,758.38
2,981.5
1,750.49
766.94
264.09
78.45
19.18
101.76
Book Value per Share
-266.96
-263.19
4,070.45
2,795.15
1,312.83
1,575.72
6,021.79
4,758.38
2,981.5
1,750.49
766.94
264.09
78.45
19.18
50.59
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
2
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
-3,614.99
-1,139.54
-525.76
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-3
-17
-9
-11
-17
-12
-10
-20
-29
-32
-18
-7
-8
-10
-11
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-3,630.19
-1,133.55
-483.61
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-2
31
21
11
15
88
69
44
30
12
10
14
16
9
Working Capital
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-2
-2
31
22
11
16
88
70
44
30
13
14
16
16
13
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-40.14
-103.94
-91.54
-19.01
-25.94
-50.47
-86.98
-81.36
-50.63
-49.77
-64.21
-68.21
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
19
16
12
Cash, Cash Equivalents & STI
18
15
11
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
2
3
Payables & Accruals
2
2
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
32.39%
-13.84%
-3.34%
Free Cash Flow
7.33%
-16.49%
7.4%
Net Income, GAAP
11.3%
-9.51%
37.14%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-16.77
-13.21
-18.46
- -
-64.61
2025
-4.91
-5.06
-2.77
- -
-19.13
2026
-2.32
-2.86
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Medical System Network Co., Ltd. (4350.T)
Paion AG (0NF3.L)
China BCT Pharmacy Group, Inc. (CNBI)
Bayer AG (BAYNN.MX)
Welcure Drugs & Pharmaceuticals Limited (WELCURE.BO)
PCI Biotech Holding ASA (0JGL.L)
Business
EoCene Ltd. is a biopharmaceutical and medical device company headquartered in Ramat Gan, Israel, that develops and seeks to commercialize therapies and technologies for gastrointestinal disease management, GI oncology and related therapeutic areas. Founded as Galmed Pharmaceuticals Ltd., the company operates through a diversified platform that includes Colospan Ltd., a wholly owned commercial-stage medical device subsidiary; its flagship CG-100 intraluminal bypass device for colorectal surgery; and its therapeutic portfolio led by Aramchol, a synthetic fatty acid-bile acid conjugate being evaluated across liver disease and oncology applications, including gastrointestinal cancers. The company’s products and services include the development of prescription therapeutics; medical devices designed to protect colorectal anastomoses and reduce diverting stomas; investigational and commercial-readiness support for device and drug programs; and related clinical development, regulatory and commercialization activities, with operations and strategic collaborations spanning Israel, Europe and the United States. In September 2026, the company rebranded from Galmed Pharmaceuticals to EoCene Ltd., changed its Nasdaq ticker from GLMD to EOCN, launched a new corporate website, regained compliance with Nasdaq’s minimum bid price requirement, and terminated its $20 million standby equity purchase agreement with Yorkville after drawing about $7.3 million; it also reported that the rebranding follows the June 2026 acquisition of Colospan and reflects its strategic shift from a liver-focused biotech toward a GI-focused medtech and biopharmaceutical platform. The company states that CG-100 has FDA Breakthrough Device Designation, CE marking under EU MDR and FDA IDE authorization for investigational use in the United States, while its broader development pipeline continues to include Aramchol and other GI-oriented initiatives.